Check for updates

OPEN ACCESS

EDITED AND REVIEWED BY Shyamala Maheswaran, Harvard Medical School, United States

*CORRESPONDENCE

Bing Liu, ⊇ liubing9909@whu.edu.cn Jian-Nan Liu, ⊇ laurence_ljn@163.com Guo-Jun Chen, ⊇ guojun.chen@mcgill.ca Chun Xu, ⊇ chun.xu@uq.edu.au Lin-Lin Bu, ⊇ lin-lin.bu@whu.edu.cn

RECEIVED 04 October 2023 ACCEPTED 14 November 2023 PUBLISHED 24 November 2023

CITATION

Liu B, Liu J-N, Chen G-J, Xu C and Bu L-L (2023), Editorial: Cuproptosis and tumor. *Front. Cell Dev. Biol.* 11:1307501. doi: 10.3389/fcell.2023.1307501

COPYRIGHT

© 2023 Liu, Liu, Chen, Xu and Bu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Editorial: Cuproptosis and tumor

Bing Liu^{1,2}*, Jian-Nan Liu³*, Guo-Jun Chen⁴*, Chun Xu⁵* and Lin-Lin Bu^{1,2}*

¹State Key Laboratory of Oral and Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei, China, ²Department of Oral and Maxillofacial—Head Neck Oncology, School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei, China, ³Department of Oral Maxillofacial—Head and Neck Oncology, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China, ⁴Department of Biomedical Engineering and Rosalind and Morris Goodman Cancer Institute, McGill University, Montreal, QC, Canada, ⁵School of Dentistry, The University of Queensland, Brisbane, QLD, Australia

KEYWORDS

cell death, cuproptosis, molecular mechanism of cuproptosis, tumor, drug delivery system

Editorial on the Research Topic Cuproptosis and tumor

As a trace element, copper is widely involved in the physiological activities of cells and plays an important role. Accumulation of copper in cells can induce oxidative stress and disrupt cellular function, thus copper homeostasis in cells is strictly regulated. Cuproptosis is a new type of programmed cell death induced by copper and is different from other types such as apoptosis, pyroptosis, and ferroptosis (Tsvetkov, et al., 2022). Copper ions bind to lipoacyl proteins during the tricarboxylic acid (TCA) cycle, leading to abnormal oligomerization of lipoacyl protein (Li, et al., 2022). In addition, the level of iron-sulfur cluster proteins can be reduced by copper ions, resulting in toxic stress reactions in proteins and leading to cell death. Cuproptosis impacts the pathogenesis of various diseases, including hepatolenticular degeneration, neurodegenerative diseases, and cancer (Wang, et al., 2023). Therefore, targeting cuprotosis may become a potential treatment method for various diseases and has attracted widespread attention.

This Research Topic focuses on the molecular mechanism of cuprotosis in the development of tumors and the potential therapeutic approach to targeting cuprotosis. Based on the significant impact of cuproptosis in the pathogenesis of colorectal cancer, Li et al. identified potential cuprotosis-related genes (CRGs) and developed a new predictive model using LASSO regression and multivariate Cox stepwise regression in the TCGA dataset, which evaluates the immune characteristics of colorectal cancer patients while predicting their prognosis. In addition, Wang et al. comprehensively analyzed the relationship between CRG and TME in colon adenocarcinoma (COAD), constructed a CRG risk scoring system, and accurately predicted the survival rate of COAD patients. The CRG risk scoring systems have provided clinical doctors with new insights to develop more effective and personalized treatment strategies. Fan et al. designed a new nomograph containing CRG scores and clinical characteristics, which can predict the 3-year, 5-year, and 7-year recurrence risk of ER + breast cancer. Liu et al. revealed the potential impact on the overall survival period, immune invasion, drug sensitivity, and metabolic spectrum of breast cancer through CRG. Similarly, scholars have also explored the prognostic value of CRG in prostate adenocarcinoma, lung adenocarcinoma, and gastric cancer.

The impact of cuproptosis on the occurrence and development of hepatocellular carcinoma, as well as its potential targets and prognostic value, seems to have aroused great interest. For example, Shao et al. and Shi et al. developed scoring models based on CRG to predict the prognosis of hepatocellular carcinoma and revealed the potential synergistic effect of novel immunotherapies such as TIGHT, CD274, and LAG-3 on cuproptosis. Cao et al. explained the characteristics of cuproptosis in hepatocellular carcinoma through single-cell sequencing and genetic multiomics and identified that BEX1 may be a key hub gene mediating cuproptosis in hepatocellular carcinoma and serve as a potential therapeutic target. Wang et al. explained the potential role of targeted cuproptosis in targeted immune microenvironment therapy for hepatocellular carcinoma and proposed that CRG can serve as a biomarker for immune checkpoint inhibitor therapy.

Although this Research Topic has collected many interesting and valuable research results, the relationship between cuproptosis and tumors still needs to be further explored. A deeper understanding of the role of cuproptosis in different tumor mechanisms should be explored, which may include aspects such as cell death, energy metabolism, and tumor immunity (Chen, et al., 2022). In addition, the role of targeted cuproptosis in tumor treatment should also be taken seriously. Recent studies have shown that inducing abnormal programmed cell death may be a potential method for treating and preventing tumor diseases. Therefore, targeting cuproptosis to increase the level of cuproptosis in tumor cells provides a new approach for tumor treatment. Cuproptosis, as an immunogenic death (ICD), can promote the release of tumor antigens, increase antigen presentation levels, promote T cell activation, and enhance antitumor immunity (Xie, et al., 2023). Therefore, targeting cuproptosis as a supplement to immunotherapy or an adjuvant therapy to improve the effectiveness of immunotherapy has enormous potential application value. The combination of cuproptosis with other therapies such as chemotherapy, radiotherapy, and photodynamic therapy has also received attention (Li, et al., 2023). Currently, drug delivery systems have received a lot of attention. The drug delivery system can accurately deliver drugs that induce cuproptosis to the tumor microenvironment. While improving the level of cuproptosis in tumor cells, it can reduce the systemic toxicity and side effects of drugs, thereby improving the survival period and quality of life of tumor patients. This will be the focus of future research.

References

Chen, L., Min, J., and Wang, F. (2022). Copper homeostasis and cuproptosis in health and disease. Signal Transduct. Target Ther. 7, 378. doi:10.1038/s41392-022-01229-y

Author contributions

BL: Writing-review and editing, Writing-original draft. J-NL: Writing-review and editing. G-JC: Writing-review and editing. CX: Writing-review and editing. L-LB: Writing-original draft, Writing-review and editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the Postdoctoral Science Foundation of China (2018M630883 and 2019T120688), the Hubei Province Chinese Medicine Research Project (ZY 2023Q015), the Natural Science Foundation of Hubei Province (2023AFB665), Wuhan Young Medical Talents Training Project to L-LB, and Medical Young Talents Program of Hubei Province.

Acknowledgments

We thank all contributing authors and reviewers for their work and dedication to this Research Topic.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Tsvetkov, P., Coy, S., Petrova, B., Dreishpoon, M., Verma, A., Abdusamad, M., et al. (2022). Copper induces cell death by targeting lipoylated TCA cycle proteins. *Science* 375, 1254–1261. doi:10.1126/science.abf0529

Wang, Q., Sun, J., Chen, T., Song, S., Hou, Y., Feng, L., et al. (2023). Ferroptosis, pyroptosis, and cuproptosis in alzheimer's disease. ACS Chem. Neurosci. 14, 3564–3587. doi:10.1021/acschemneuro.3c00343

Xie, J., Yang, Y., Gao, Y., and He, J. (2023). Cuproptosis: mechanisms and links with cancers. *Mol. Cancer* 22, 46. doi:10.1186/s12943-023-01732-y

Li, S. R., Bu, L. L., and Cai, L. (2022). Cuproptosis: lipoylated TCA cycle proteinsmediated novel cell death pathway. *Signal Transduct. Target Ther.* 7, 158. doi:10.1038/ s41392-022-01014-x

Li, Z. Z., He, J. Y., Wu, Q., Liu, B., and Bu, L. L. (2023). Recent advances in targeting myeloid-derived suppressor cells and their applications to radiotherapy. *Int. Rev. Cell Mol. Biol.* 378, 233–264. doi:10.1016/bs.ircmb.2023.03.007